OraSure Technologies Stock News

OraSure is an underfollowed name with strong growth potential selling simple to use COVID-19 rapid test kits, given another wave of virus spread is approaching during the winter. With over $3 in cash

OraSure Technologies Inc (NASDAQ: OSUR) has secured a $109 million contract from the U.S. Department of Defense to build additional manufacturing capacity in the U.S. for InteliSwab COVID-19 rapid

Agreement Ensures OraSure Will Have Sufficient Capacity to Meet Market Need for Rapid Antigen Tests and Ensure Future Preparedness Agreement Ensures OraSure Will Have Sufficient Capacity to Meet Marke

BETHLEHEM, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced

BETHLEHEM, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q2 2021 Results - Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of -150.00% and 1.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of OraSure Technologies (NASDAQ:OSUR) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 87.50% over the past year to ($0.02), w

Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET

BETHLEHEM, Pa., June 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and ana

Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease Status Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease S

OraSure Technologies Inc (NASDAQ: OSUR) has received FDA Emergency Use Authorization (EUA) for its COVID-19 rapid antigen tests, InteliSwab. These tests detect active COVID-19 infection; the agency

Branded as InteliSwab™, the easy-to-use diagnostic tests rapidly detect active COVID-19 infection Branded as InteliSwab™, the easy-to-use diagnostic tests rapidly detect active COVID-19 infection

BETHLEHEM, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytic

OraSure Technologies Inc (NASDAQ: OSUR) has resubmitted two separate Emergency Use Authorization (EUA) applications for its SARS-CoV-2 Antibody ELISA and the oral specimen collection device. ELISA is